We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

5 hedge funds and large institutions have $424K invested in Monopar Therapeutics in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more capital invested

Capital invested by funds: $132K → $424K (+$292K)

0.07% more ownership

Funds ownership: 0.03% → 0.11% (+0.07%)

29% less funds holding

Funds holding: 7 → 5 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
+$382K
2
BlackRock
BlackRock
New York
+$6.34K
3
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$1.31K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$85K
2
Victory Capital Management
Victory Capital Management
Texas
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
1
Northern Trust
Illinois
$372K +$382K +9,951 New
BlackRock
2
BlackRock
New York
$27K +$6.34K +165 +29%
Morgan Stanley
3
Morgan Stanley
New York
$24K – – –
CAPTRUST Financial Advisors
4
CAPTRUST Financial Advisors
North Carolina
$1K +$1.31K +34 New
Millennium Management
5
Millennium Management
New York
– -$85K -2,301 Closed
Victory Capital Management
6
Victory Capital Management
Texas
– -$4K -138 Closed

MNPR Hedge Fund Activity: Q2 2020 in Review

5 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2020, worth a combined $424K — up 221% from $132K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MNPR and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Northern Trust, opening a new position worth an estimated $382K. The largest seller was Millennium Management, exiting entirely with an estimated $85K sold.

  • 5 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2020, down from 7 in Q1 2020.
  • Funds reported $424K of Monopar Therapeutics stock for Q2 2020, up 221% quarter-over-quarter.
  • 2 funds opened new Monopar Therapeutics positions in Q2 2020 and 4 closed out, a net change of -2 holders.
  • The largest Monopar Therapeutics buyer in Q2 2020 was Northern Trust, an estimated $382K added.
  • The largest Monopar Therapeutics seller in Q2 2020 was Millennium Management, an estimated $85K sold.

Based on aggregated 13F filings for Q2 2020.